NLS Acquisition

Thermo Fisher Scientific has announced a definitive agreement to acquire Clario Holdings, a provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for USD 8.875 billion in cash at close plus potential additional earnout and other payments in the future, largely dependent on performance.

The acquisition of Metsera, including its early and development-stage incretin and non-incretin analogue peptide programmes, would provide Novo Nordisk the opportunity to maximize the potential of Metsera’s complementary portfolio and capabilities, it states.

Novartis has entered into an agreement to acquire Avidity Biosciences, a San Diego-based, biopharmaceutical company focused on a new class of therapeutics enabling RNA delivery to muscle.

Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need.

The two companies have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion.

The company's board has decided to initiate a process to seek potential stakeholders for a reverse take over of the company with the aim to materialize the value of its public listing.